» Articles » PMID: 19497660

Regulation of BIRC5 and Its Isoform BIRC5-2B in Neuroblastoma

Overview
Journal Cancer Lett
Specialty Oncology
Date 2009 Jun 6
PMID 19497660
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We analysed the expression of BIRC5 and BIRC5-2B in primary neuroblastoma (NB) tumors and NB model systems. In tumors, overexpression of BIRC5 correlated closely with its isoform BIRC5-2B. Expression of both transcripts was stage-dependent, associated with poor prognosis and with the expression of the transcription factor E2F1. In cell culture, we identified BIRC5 as a direct transcriptional target of activating E2Fs, primarily when p21(Cip1) and p27(Kip1), two other E2F1 targets, are strongly suppressed. Deregulated MYCN indirectly induces BIRC5 through suppression of CDKN1A/p21(Cip1) and induction of Skp2, which in turn favors the degradation of p27(Kip1). In addition, increased BIRC5 protein stability via phosphorylation is mediated by expression of E2F targets such as CDC2. In line with this, selective knock down of CDC2 inhibited BIRC5 abundance and suppressed its anti-apoptotic activities. We conclude that BIRC5 is induced via a functional cooperation between MYCN and E2F1.

Citing Articles

MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.

Salib A, Jayatilleke N, Seneviratne J, Mayoh C, De Preter K, Speleman F Oncogene. 2023; 43(5):363-377.

PMID: 38049564 PMC: 10824661. DOI: 10.1038/s41388-023-02897-y.


Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma.

Kang W, Hu J, Zhao Q, Song F Front Cell Dev Biol. 2021; 9:731380.

PMID: 34746127 PMC: 8567030. DOI: 10.3389/fcell.2021.731380.


Epigenetic Targeting of -Associated Gene Expression Signature in Human Neuroblastoma with Overexpression.

Huang M, Zeki J, Sumarsono N, Coles G, Taylor J, Danzer E Cancer Res. 2020; 80(5):1024-1035.

PMID: 31900258 PMC: 7056551. DOI: 10.1158/0008-5472.CAN-19-2560.


MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.

Aygun N, Altungoz O Mol Med Rep. 2018; 19(1):345-361.

PMID: 30483774 PMC: 6297758. DOI: 10.3892/mmr.2018.9686.


TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Decaesteker B, Denecker G, Van Neste C, Dolman E, Van Loocke W, Gartlgruber M Nat Commun. 2018; 9(1):4866.

PMID: 30451831 PMC: 6242972. DOI: 10.1038/s41467-018-06699-9.